Is intramuscular administration of Invanz (meropenem) appropriate, and what are the recommended doses for adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Invanz Intramuscular Administration

Invanz (ertapenem, not meropenem) can be administered intramuscularly, but this is a critical distinction—the question appears to confuse Invanz with meropenem, which are different carbapenems with different administration routes.

Clarification of Drug Identity

  • Invanz is the brand name for ertapenem, not meropenem 1
  • Ertapenem is specifically approved for intramuscular administration, while meropenem is administered intravenously or intramuscularly in limited contexts 2, 1
  • The evidence provided focuses primarily on meropenem, which is marketed as Merrem or Meronem, not Invanz 3

Ertapenem (Invanz) Intramuscular Dosing

Adult Dosing

  • Standard IM dose: 1 gram once daily for complicated intra-abdominal infections and other approved indications 1
  • Ertapenem offers the advantage of once-daily dosing compared to other carbapenems that require multiple daily doses 1

Pediatric Dosing

  • Children 3 months to 12 years: 15 mg/kg twice daily intramuscularly (maximum 1 gram/day) 1
  • Children ≥13 years: 1 gram once daily (adult dosing) 1
  • The twice-daily pediatric dosing differs significantly from the once-daily adult regimen 1

Meropenem Administration Routes (For Comparison)

  • Meropenem is NOT routinely given intramuscularly in most clinical guidelines 2, 1
  • Meropenem is primarily administered intravenously by bolus injection (over 5 minutes) or infusion (15-30 minutes) 4, 3
  • Limited evidence supports intramuscular meropenem use in specific tuberculosis treatment protocols at 600-800 mg daily 2
  • For severe infections, meropenem requires intravenous administration at 1-2 grams every 8 hours 1, 5

Clinical Considerations

When to Choose Ertapenem (Invanz) IM

  • Community-acquired complicated intra-abdominal infections in non-critically ill patients where once-daily dosing is advantageous 1
  • Patients requiring carbapenem therapy but lacking reliable intravenous access 1
  • Step-down therapy from IV meropenem when continued parenteral therapy is needed but outpatient administration is desired 5

When Ertapenem is INADEQUATE

  • Pseudomonas aeruginosa infections: Ertapenem lacks antipseudomonal activity; meropenem IV is required 1, 5
  • Critically ill patients with healthcare-associated infections: Require broader-spectrum IV carbapenems like meropenem 1, 5
  • Central nervous system infections: Ertapenem does not achieve adequate CNS penetration; meropenem 2 grams IV every 8 hours is required for meningitis 5
  • Carbapenem-resistant organisms: Require high-dose meropenem with extended infusion, not ertapenem 5

Common Pitfalls to Avoid

  • Do not confuse Invanz (ertapenem) with meropenem—they have different spectra of activity and administration requirements 1, 3
  • Do not use ertapenem for Pseudomonas coverage—it is inactive against this pathogen 1
  • Do not use intramuscular administration for critically ill or hemodynamically unstable patients—intravenous access is mandatory for reliable drug delivery 1
  • Do not assume once-daily dosing applies to all carbapenems—only ertapenem has this pharmacokinetic profile 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.